title: Kaposi's sarcoma following immunosuppressive therapy for vasculitis.
abstract: Kaposi's sarcoma (KS) is widely reported to develop after renal transplantation and is induced by activation of a latent human herpes virus 8. We report the clinical features and outcome of a 50-year-old woman who presented with KS 18 weeks after starting immunosuppressive therapy for vasculitis. She had positive-titer IgG antibody to human herpes virus 8. Cyclophosphamide pulses were interrupted, and prednisone was decreased gradually to 10 mg/day. Skin lesions showed important regression with stabilization of the general state and renal function. Eight months later, the patient presented with a diffuse cutaneous KS that required the discontinuation of steroids. Within 1 month, her general status and renal function deteriorated, and she died with a disseminated intravascular coagulation syndrome.
authors.affiliation: Unit of Nephrology, Dialysis, Renal Transplantation, Ibn Sina University Hospital, Rabat, Morocco. tarik1008@hotmail.com
authors.forename: Tarik
authors.initials: T
authors.lastname: Bouattar
authors.forename: Laila
authors.initials: L
authors.lastname: Kazmouhi
authors.forename: Zaitouna
authors.initials: Z
authors.lastname: Alhamany
authors.forename: Kawtar
authors.initials: K
authors.lastname: Beqqal
authors.forename: Laila
authors.initials: L
authors.lastname: Haffane
authors.forename: Tarik Sqalli
authors.initials: TS
authors.lastname: Houssaini
authors.forename: Hakima
authors.initials: H
authors.lastname: Rhou
authors.forename: Loubna
authors.initials: L
authors.lastname: Benamar
authors.forename: Karima
authors.initials: K
authors.lastname: Senouci
authors.forename: Rabia
authors.initials: R
authors.lastname: Bayahia
authors.forename: Naima
authors.initials: N
authors.lastname: Ouzeddoun
mesh_terms: D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy* / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000276:immunology; D019288:Herpesvirus 8, Human / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000139:chemically induced* / Q000473:pathology / Q000821:virology; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects*; D020551:Pulse Therapy, Drug; D006435:Renal Dialysis; D012514:Sarcoma, Kaposi / Q000139:chemically induced* / Q000473:pathology / Q000821:virology; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011241:Prednisone